Jan Hirsch, BSPharm, PhD, Faculty Director, is a Professor of Clinical Pharmacy, and Chair of the Division of Clinical Pharmacy at the Skaggs School of Pharmacy and Pharmaceutical Sciences (SSPPS), at the University of California, San Diego. She also serves as Executive Director of Partners in Medication Therapy (PMT), an outreach program of the school providing medication therapy management services in the community. In addition, she is a Clinical Pharmacist Specialist at the Veterans Affairs of San Diego Healthcare System working in the formulary and pharmacoeconomics group.
She received her BS in Pharmacy and MS and PhD degrees in Pharmacy Administration (emphasis areas marketing and economics) from the University of South Carolina, College of Pharmacy. Prior to joining the UCSD faculty, she spent 14 years in the pharmaceutical and managed care industries where she was responsible for establishing and managing outcomes research departments for two pharmaceutical companies [Glaxo Group Research in Greenford (UK) and Allergan (US)] and a pharmacy benefit management company [Prescription Solutions (now OptumRx) (US)].
Dr. Hirsch is heavily involved in teaching professionals from pharmacy and medical students to working professionals in multi-disciplinary bio-pharmaceutical job functions across countries. As a founding faculty member of the school of pharmacy she has been responsible for creating and teaching three of its required courses, Health Policy, Study Design and Pharmacoeconomics, the course she currently teaches. She has received an Excellence in Teaching Award for her work. Her teaching activities also encompass lectures given at UC San Diego’s Rady School of Management, and UC San Diego’s Master of Advanced Studies in Clinical Research program. She is a trainer in the American Pharmacists Association Medication Therapy Management Certificate Program for practicing pharmacists and has recently collaborated with UC San Diego Extension, and Utrecht University, Netherlands to create and deliver an online certificate program in the Drug Development Process for working bio-pharmaceutical professionals.
Dr. Hirsch’s research interests are focused in the areas of pharmacoeconomics and outcomes research. Specifically, 1) assessing the full value (economic, clinical and humanistic) of pharmacy services and pharmaceuticals in clinical trials or observational studies across therapeutic areas; and 2) integrating patient reported outcomes (PRO’s) (e.g. burden elements, Quality of Life, satisfaction) into pharmaceutical and medical care practices to improve patient management – with emphasis on: developing and validating PRO instruments, assessing outcomes status in patient populations, and identifying patients who will likely benefit most – realize greatest value – from interventions. Key current therapeutic areas of interest: diabetes, gout, HIV/AIDS, hypertension, mental health, and specialty pharmaceuticals.
Her clinical interests include development, implementation and evaluation of innovative Medication Therapy Management (MTM) practice models in community healthcare settings to improve the quality of patient care in a cost-effective manner. She is also involved with formulary management activities within the VA to improve clinical outcomes and responsibly manage medical costs.
She serves on multiple committees at the SSPPS, Health Sciences, and Campus levels at UCSD and is chair of the Annual Applied Pharmacoeconomics and Outcomes Research Forum invitational conference. She has held leadership roles at the state and national level including California Pharmacists Association, California Right Care Initiative (public-private collaborative of health-system stakeholders focused on improving clinical outcomes through enhanced patient-centered, evidence-based medicine), National Medication Management Collaborative, and the American Pharmacists Association.
“This program will create innovative thinkers with an uncommon knowledge base and broad sense of the challenges and strategies that occur along the drug development and post-marketing continuum from first human clinical trials through drug utilization in a vast array of populations.”
– Jan D. Hirsch, BSPharm, PhD